Chimigen completes its first round of Pre-A financing exceeding 100 million yuan, accelerating its global expansion of cancer therapeutic vaccines

On February 18, 2025 Chimigen Biomedical, which focuses on the development of innovative therapeutic vaccines, reported the completion of the first tranche of its Pre-A round of financing. This round was led by SDIC Venture Capital and followed by CAS Star , raising over 100 million yuan. The funds will be used to accelerate the global clinical trials of its core products SN3001 (a therapeutic vaccine for prostate cancer) and SN2001 (an immunotherapy vaccine for chronic hepatitis B), as well as to continue the development of its oncology therapeutic vaccine products based on the SynNeogen core technology platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Shi Yuenian, founder of KemiBio, stated: "We warmly welcome SDIC Venture Capital and CAS Star as new shareholders of the company. Against the backdrop of the current industry capital winter, KemiBio’s first hurdle in this round of financing fully demonstrates the capital’s high recognition of our platform technology and the clinical value and commercial prospects of our core pipeline. As an innovation-driven company founded during the pandemic and growing amidst a capital winter, we focus on immunotherapy for oncology and viral infections, and are committed to building a globally competitive and differentiated product pipeline. We especially thank our new and existing shareholders for their strong support at this crucial stage of the company’s development. KemiBio will continue to deepen its R&D philosophy of ‘innovation-led, science-based,’ accelerate the development of multiple therapeutic vaccine products with internationally leading levels and significant clinical value, achieve clinical translation capabilities through groundbreaking innovative technologies, and contribute social value to global health."

(Press release, Chimigen Biomedical, FEB 18, 2025, View Source [SID1234673517])